Trials / Completed
CompletedNCT06423872
A SAD Study of ZT002 Injection in Healthy Participants
A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZT002 | Participants will receive a single subcutaneous (SC) ZT002 injection. |
| OTHER | Placebo | Participants will receive same volume as of the study drug. |
Timeline
- Start date
- 2023-06-19
- Primary completion
- 2023-10-20
- Completion
- 2023-12-08
- First posted
- 2024-05-21
- Last updated
- 2024-05-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06423872. Inclusion in this directory is not an endorsement.